Cell-associated HIV DNA identified in CSF in nearly half of participants, tied to worse neurocognitive outcomes.
When comparing hormonal contraceptive methods, particularly IM depot medroxyprogesterone acetate with an IUD and a levonorgestrel implant, there was no substantial difference in HIV risk among African women.
Algorithms use data from EHRs to identify candidates for preexposure prophylaxis.
The novel Fujifilm SILVAMP TB LAM assay offers superior diagnostic sensitivity while also maintaining specificity, compared with standard assay.
In the 50 local jurisdictions with concentration of most new HIV infections, testing was 46.9%.
Despite ART, children with HIV have a high incidence of cardiac abnormalities, with only a minority of cases being transient in nature.
USPSTF has updated its recommendations on HIV screening and has assigned a Grade A for a new recommendation to offer PrEP for all persons at high risk for HIV infection.
No significant difference seen with use of DMPA-IM, copper IUD device, levonorgestrel implant in African women.
Algorithms may help predict cardiovascular disease risk in people living with HIV.
There is zero risk for HIV transmission in serodiscordant gay couples through condomless sex when the partner with HIV is receiving suppressive ART.
Limiting acute viremia results in enhanced functionality of HIV-specific CD4+ and CD8+ T cells.
A scientific statement from the American Heart Association was published in Circulation, with the purpose of providing a thorough review of available evidence on HIV-associated cardiovascular disease.
Gradually increasing intensity of treatment reduces alcohol intake and improves HIV status.
Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination.
Overall, 71.2% have viral suppression, including 35.2% of those with high probability of viremia.
The New Drug Application (NDA) for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for patients with HIV-1 infection has been submitted to the Food and Drug Administration (FDA).
Activists have been urging Gilead to make the generic drug more widely available.
Truvada is approved in combination with safer sex practices for HIV-1 PrEP to reduce the risk of sexually acquired HIV-1.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Zero rate of HIV transmission seen through condomless sex when viral load is suppressed